Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioNTech fires shots at Moderna's next-generation vaccine

20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.

Careers

Mintz gains ex-Winston & Strawn partner and ITC expert

20 February 2026 The new hire has “deep experience in high-stakes International Trade Commission proceedings”, whose specialisms include medical devices, pharma and genomics.

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

More features

Semaglutide patent battle heats up with new blow for Novo in India

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features